www.fdanews.com/articles/61229-solvay-seiyaku-eisai-collaborate-on-sa-001
SOLVAY SEIYAKU, EISAI COLLABORATE ON SA-001
July 27, 2006
Switzerland-based Solvay Pharmaceuticals Marketing & Licensing AG, an affiliate of Solvay Pharmaceuticals (Brussels, Belgium) and Eisai Co. Ltd. concluded a license agreement on Solvay Pharmaceuticals' treatment for pancreatic exocrine insufficiency (SA-001) in Japan.
BioSpectrum (http://www.biospectrumasia.com/content/270706JPN1232.asp)